Observation on the Immune Persistence of People Aged 10-60 Years Old Immunized With Five Doses of Rabies Vaccine

Single Arm, Single Center Phase IV Clinical Trial to Evaluate the Immune Persistence and Safety of Freeze-dried Human Rabies Vaccine (Vero Cell)

Evaluation of immune persistence after rabies vaccination in 150 people.

150 subjects aged 10-60 were recruited to inoculate the frozen human rabies vaccine (Vero cells) produced and marketed by Changchun Zhuoyi Biological Co., Ltd. in the whole process of 0, 3, 7, 14 and 28 day immunization. The immunogenicity persistence and safety of the test vaccine were evaluated 14 days, 6 months and 12 months after the whole process of vaccination.

Inclusion Criteria:

• 10-60 years old；
• Temperature on the day of admission≤37.0 ° C (axillary temperature).

Exclusion Criteria:

• Have a history of rabies vaccine immunization or use of rabies virus passive immunization agents；
• Has been diagnosed with congenital or acquired immunodeficiency disease;
• Pregnancy (including positive urine pregnancy test) or lactation, planned pregnancy preparation within 2 months.